269 related articles for article (PubMed ID: 33047897)
1. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.
van Ballegoij WJC; van de Stadt SIW; Huffnagel IC; Kemp S; Willemse EAJ; Teunissen CE; Engelen M
Ann Clin Transl Neurol; 2020 Nov; 7(11):2127-2136. PubMed ID: 33047897
[TBL] [Abstract][Full Text] [Related]
2. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
4. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
5. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal diffusion MRI as surrogate outcome measure for myelopathy in adrenoleukodystrophy.
Huffnagel IC; van Ballegoij WJC; Vos JMBW; Kemp S; Caan MWA; Engelen M
Neurology; 2019 Dec; 93(23):e2133-e2143. PubMed ID: 31719133
[TBL] [Abstract][Full Text] [Related]
8. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
9. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
[TBL] [Abstract][Full Text] [Related]
11. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
[TBL] [Abstract][Full Text] [Related]
12. High Levels of NfL, GFAP, TAU, and UCH-L1 as Potential Predictor Biomarkers of Severity and Lethality in Acute COVID-19.
Salvio AL; Fernandes RA; Ferreira HFA; Duarte LA; Gutman EG; Raposo-Vedovi JV; Filho CHFR; da Costa Nunes Pimentel Coelho WL; Passos GF; Andraus MEC; da Costa Gonçalves JP; Cavalcanti MG; Amaro MP; Kader R; de Andrade Medronho R; Figueiredo CP; Amado-Leon LA; Alves-Leon SV
Mol Neurobiol; 2024 Jun; 61(6):3545-3558. PubMed ID: 37996731
[TBL] [Abstract][Full Text] [Related]
13. Spinal cord atrophy as a measure of severity of myelopathy in adrenoleukodystrophy.
van de Stadt SIW; van Ballegoij WJC; Labounek R; Huffnagel IC; Kemp S; Nestrasil I; Engelen M
J Inherit Metab Dis; 2020 Jul; 43(4):852-860. PubMed ID: 32077106
[TBL] [Abstract][Full Text] [Related]
14. Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI.
Shahim P; Politis A; van der Merwe A; Moore B; Ekanayake V; Lippa SM; Chou YY; Pham DL; Butman JA; Diaz-Arrastia R; Zetterberg H; Blennow K; Gill JM; Brody DL; Chan L
Neurology; 2020 Aug; 95(6):e623-e636. PubMed ID: 32641529
[TBL] [Abstract][Full Text] [Related]
15. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
[TBL] [Abstract][Full Text] [Related]
16. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease.
Kim H; Lee EJ; Kim S; Choi LK; Kim K; Kim HW; Kim KK; Lim YM
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32184342
[TBL] [Abstract][Full Text] [Related]
17. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
[TBL] [Abstract][Full Text] [Related]
18. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
[TBL] [Abstract][Full Text] [Related]
19. Neurofilament light chain but not glial fibrillary acidic protein is a potential biomarker of overt hepatic encephalopathy in patients with cirrhosis.
de Wit K; van Doorn DJ; Mol B; van Vught LA; Nevens F; Beuers U; Ponsioen CY; Teunissen CE; Takkenberg RB
Ann Hepatol; 2024; 29(3):101496. PubMed ID: 38460714
[TBL] [Abstract][Full Text] [Related]
20. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI.
Gill J; Latour L; Diaz-Arrastia R; Motamedi V; Turtzo C; Shahim P; Mondello S; DeVoto C; Veras E; Hanlon D; Song L; Jeromin A
Neurology; 2018 Oct; 91(15):e1385-e1389. PubMed ID: 30209234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
